Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort

Journal of Bone Oncology

Volumn 2, Issue 1, 2013, Pages 2-10

  Hadji, Peyman ^a   Frank, Matthias ^b   Jakob, Andreas ^b   Siebers, Jan Willem ^b  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b Klinikum Offenburg   (Germany)

Author keywords

Adjuvant therapy; Bisphosphonates; Breast cancer; Disease free survival; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IBANDRONIC ACID; PROGESTERONE RECEPTOR; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 84882297750     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2013.01.001     Document Type: Article

References (32)

1. Aebi S, Davidson T, Gruber G, Castiglione M. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl. 5): v9-14.
2. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28(23): 3784-96.
3. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009;69(1): 73-82.
4. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008;112(5): 1001-10. (Pubitemid 351304583)
5. Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, et al. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? Clin Breast Cancer 2009;9(Suppl. 1): S18-27.
6. Amgen Inc. Xgevas (denosumab) injection [package insert],/http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/125320s007lbl.pdfS; 2010 (accessed 26.07.2012).
7. National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology: Breast Cancer,/V2.2011. www.nccn.comS; (accessed 26.06.2012).
8. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, et al. Oral bisphosphonate use and breast cancer incidence in postmeno-pausal women. J Clin Oncol 2010;28(22): 3582-90.
9. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010;102(5): 799-802.
10. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010;28(22): 3577-81.
11. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34(5): 453-75.
12. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol 2010;37(Suppl. 1): S53-65.
13. Lipton A. Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates. Expert Opin Pharmacother 2011;12(5): 749-62.
14. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11(5): 421-8.
15. Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow (abstract 559). In: Poster presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL: May 30-Jun 3; 2008.
16. Rack B, Juckstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010;30(5): 1807-13.
17. Solomayer E, Gebauer G, Hirnle P, Janni W, Lück HJ, Becker S, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients (abstract 2048). Cancer Res 2009;69(Suppl. 1): 170s-1s.
18. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010;21(11): 2188-94.
19. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360(7): 679-91.
20. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008;19(12): 2007-11.
21. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006;8(2): R13.
22. Mauri D, Valachis A, Polyzos NP, Tsali L, Mavroudis D, Georgoulias V, et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw 2010;8(3): 279-86.
23. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365(15): 1396-405.
24. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339(6): 357-63. (Pubitemid 28363797)
25. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20(15): 3219-24. (Pubitemid 34831518)
26. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19(1): 10-7. (Pubitemid 32063474)
27. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43(7): 650-6. (Pubitemid 39563937)
28. Coleman R, Marshall H, Gregory W, Bell R, Dodwell D, Keane M, et al. Discordant treatment effects according to menopausal status following adjuvant zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04) (abstract 5019). Eur J Cancer 2011;47(1): S336.
29. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H, Dubsky P, Jakesz R, et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer (abstract S1-2). In: Presented at: CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX: Dec 6-10; 2011.
30. de Boer R, Bundred N, Eidtmann H, Llombart A, von Minckwitz G, Martin N, et al. The effect of zoledronic acid on aromatase-inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up (abstract P5-11-01). In: Poster presented at: CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX: Dec 8-12; 2010.
31. Amgen, Daiichi Sankyo. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). Available at:/http://www.clinicaltrials.gov/ct2/show/NCT01077154?term= denosumab+early+breast+cancer&rank=1S; (accessed 19.12.2012).
32. Southwest Oncology Group, National Cancer Institute, North Central Cancer Treatment Group, Eastern Cooperative Oncology Group, National Surgical Adjuvant Breast and Bowel Project, Cancer and Leukemia Group B, et al. Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for Stage I, Stage II, or Stage III breast cancer. Available at:/http://www. clinicaltrials.gov/ct2/show/NCT00127205?term=SWOG+0307&rank=2S; (accessed 20.12.2012).